20 S-Hydroxyvitamin D3, Noncalcemic Product of CYP11A1 Action on Vitamin D3, Exhibits Potent Antifibrogenic Activity in Vivo
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
CONTEXT: There is no effective treatment for systemic sclerosis and related fibrosing diseases. Recently the action of CYP11A1 on vitamin D(3) was shown to produce biologically active 20S-hydroxyvitamin D [20(OH)D(3)] and 20,23(OH)(2)D(3), 20,22(OH)(2)D(3), and 17,20,23(OH)(3)D(3). OBJECTIVES: Because 20(OH)D(3) is noncalcemic (nontoxic) in vivo at very high doses, we evaluated its antifibrogenic activities both in vitro and in vivo. Because it is further metabolized by CYP11A1, we also tested preclinical utilities of its hydroxyderivatives, especially 20,23(OH)(2)D(3). DESIGN: Human dermal fibroblasts from scleroderma and normal donors were used to test the efficiency of hydroxyvitamin D derivatives in inhibiting TGF-β1-induced collagen and hyaluronan synthesis and inhibiting cell proliferation. The in vivo activity of 20(OH)D(3) was tested using bleomycin-induced sclerosis in C57BL/6 mice. RESULTS: 20(OH)D(3) and 20,23(OH)(2)D(3) inhibited TGF-β1-induced collagen and hyaluronan synthesis similarly to 1,25(OH)(2)D(3) in cultured human fibroblasts. Also, 20(OH)D(3), 20,23(OH)(2)D(3), and 1,25(OH)(2)D(3) suppressed TGF-β1-induced expression of COL1A2, COL3A1, and hyaluronan synthase-2 mRNA, indicating that they regulate these matrix components at the transcriptional level. 20(OH)D(3), 20,23(OH)(2)D(3), 20,22(OH)(2)D(3), and 17,20,23(OH)(3)D(3) inhibited proliferation of dermal fibroblasts with comparable potency with 1,25(OH)(2)D(3), with 20(OH)D(2) being less active and 1α(OH)D(3) being almost inactive. 20,23(OH)(2)D(3) at 3 μg/kg had no effect on serum Ca(++) or fibroblast growth factor-23 levels and did not cause any noticeable signs of morbidity. 20(OH)D(3) markedly suppressed fibrogenesis in mice given sc bleomycin as demonstrated by total collagen content and hematoxylin and eosin staining of skin biopsies. CONCLUSIONS: 20(OH)D(3) is an excellent candidate for preclinical studies on scleroderma, with other CYP11A1-derived products of its metabolism deserving further testing for antibrogenic activity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, 20(OH)D3 and 20,23(OH)2D3 showed anti-fibrosing effects in vitro, and also in vivo for the former.”
From The role of CYP11A1 in the production of vitamin D metabolites and their role in the regulation of epidermal functions (2014) · cites this paper as [86]
In the citing paper
“20(OH)D3 inhibited bleomycin-induced fibrosis in C57BL/6 mice in vivo at a dose of 3 μg/kg, [86], well within its non-calcemic range”
From The role of CYP11A1 in the production of vitamin D metabolites and their role in the regulation of epidermal functions (2014) · cites this paper as [86]
In the citing paper
“We repeated the calcemic testing of 20(OH)D3, 20,23(OH)2D3 and 20(OH)D2 in mice [59,83,86] and this also showed that these secosteroids lack calcemic effects.”
From The role of CYP11A1 in the production of vitamin D metabolites and their role in the regulation of epidermal functions (2014) · cites this paper as [86]
In the citing paper
“Both 20(OH)D3 and 20,23(OH)2D3 displayed similar anti-fibrotic activities on human dermal fibroblasts from scleroderma or normal donors”
From The role of CYP11A1 in the production of vitamin D metabolites and their role in the regulation of epidermal functions (2014) · cites this paper as [86]
In the citing paper
“This demonstrates an in vivo anti-fibrosing potential for 20(OH)D3.”
From The role of CYP11A1 in the production of vitamin D metabolites and their role in the regulation of epidermal functions (2014) · cites this paper as [86]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Holick, M. F. (2007) · New England Journal of Medicine · doi:10.1056/nejmra070553 · Cited by 13,720
Vitamin D, disease and therapeutic opportunities
Plum, L. A., & DeLuca, H. F. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3318 · Cited by 477
Raghow, R., Postlethwaite, A. E., Keski-Oja, J., Moses, H. L., & Kang, A. H. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112950 · Cited by 464
Self-citationTransforming growth factor β as a therapeutic target in systemic sclerosis
Varga, J., & Pasche, B. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.26 · Cited by 295
Slominski, A. T., Kim, T., Shehabi, H. Z., Semak, I., Tang, E. K. Y., Nguyen, M. N., Benson, H. A. E., Korik, E., Janjetovic, Z., Chen, J., et al. (2012) · The FASEB Journal · doi:10.1096/fj.12-208975 · Cited by 266
Self-citationThe Complex Role of Vitamin D in Autoimmune Diseases
Szodoray, P., Nakken, B., Gaal, J., Jonsson, R., Szegedi, A., Zold, E., Szegedi, G., Brun, J. G., Gesztelyi, R., Zeher, M., et al. (2008) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2008.02127.x · Cited by 234
Guryev, O., Carvalho, R. A., Usanov, S., Gilep, A., & Estabrook, R. W. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2336107100 · Cited by 170
The cytochrome P450scc system opens an alternate pathway of vitamin D3 metabolism
Slominski, A., Semak, I., Zjawiony, J., Wortsman, J., Li, W., Szczesniewski, A., & Tuckey, R. C. (2005) · The FEBS Journal · doi:10.1111/j.1742-4658.2005.04819.x · Cited by 155
Self-citationVitamin D: newly discovered actions require reconsideration of physiologic requirements
Bikle, D. D. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.01.003 · Cited by 152
Slominski, A. T., Janjetovic, Z., Fuller, B. E., Zmijewski, M. A., Tuckey, R. C., Nguyen, M. N., Sweatman, T., Li, W., Zjawiony, J., Miller, D., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009907 · Cited by 149
Self-citation
Cited by
Fibroblasts in fibrosis: novel roles and mediators
Kendall, R. T., & Feghali-Bostwick, C. A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00123 · Cited by 1,082
Pathogenesis of Systemic Sclerosis
Pattanaik, D., Brown, M., Postlethwaite, B. C., & Postlethwaite, A. E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00272 · Cited by 405
“20(OH)D3 also suppressed development of dermal fibrosis in the BLM, scleroderma mouse model (413).”
BackgroundSelf-citationKey role of CRF in the skin stress response system
Slominski, A. T., Zmijewski, M. A., Zbytek, B., Tobin, D. J., Theoharides, T. C., & Rivier, J. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1092 · Cited by 400
Self-citationNovel activities of CYP11A1 and their potential physiological significance
Slominski, A. T., Li, W., Kim, T.-K., Semak, I., Wang, J., Zjawiony, J. K., & Tuckey, R. C. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.11.010 · Cited by 292
“Pharmacologically administered 20(OH) D3 shows antifibrotic activities both in vitro [57,117,118] and in vivo in bleomycin induced scleroderma [118].”
Self-citationSlominski, A. T., Kim, T., Takeda, Y., Janjetovic, Z., Brożyna, A. A., Skobowiat, C., Wang, J., Postlethwaite, A., Li, W., Tuckey, R. C., et al. (2014) · The FASEB Journal · doi:10.1096/fj.13-242040 · Cited by 269
“In this study, we document for the first time that novel vitamin D derivatives, including 20(OH)D3 and 20, 23(OH)2D3, act as antagonists of ROR - and ROR - mediated transactivation, which is in addition to their actions as partial agonists on the VDR (37).”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- Slominski, A., Janjetovic, Z., Tuckey, R. C., Nguyen, M. N., Bhattacharya, K. G., Wang, J., Li, W., Jiao, Y., Gu, W., Brown, M., & Postlethwaite, A. E.
- Affiliations
- University of Tennessee Health Science Center (US)
- The University of Western Australia (AU)
- Campbell Clinic (US)
- Corresponding author
- Slominski, Andrzej
- Postlethwaite, Arnold E.
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-02
- Volume
- 98
- Issue
- 2
- Pages
- E298-E303
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC3565109
- OpenAlex
- W1972743589
- Cited by
- 89
- References
- 25
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 8 · 2023: 2 · 2022: 7 · 2021: 13 · 2020: 9 · 2018: 5 · 2017: 2 · 2016: 10 · 2015: 12 · 2014: 13 · 2013: 5
- FWCI
- 10.22
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Funders
- National Institutes of Health
- U.S. Public Health Service (R01A052190)
- Health Science Center, University of Tennessee
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR052190, R21AR063242, R01AR056666)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Vitamin D Research Studies
- Health Sciences › Medicine › Rheumatology › Dupuytren's Contracture and Treatments
- Keywords
- CYP11A1, vitamin D3 metabolism, systemic sclerosis, TGF-β1, collagen synthesis, hyaluronan synthesis, dermal fibroblasts, bleomycin-induced lung fibrosis, 1,25-dihydroxyvitamin D3
- MeSH terms
- Animals, Calcifediol, Cells, Cultured, Collagen, Disease Models, Animal, Fibroblasts, Humans, Hyaluronic Acid, Mice, Inbred C57BL, Scleroderma, Systemic, Skin, Cell Proliferation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 20 S-Hydroxyvitamin D3, Noncalcemic Product of CYP11A1 Action on Vitamin D3, Exhibits Potent Antifibrogenic Activity in Vivo. https://app.cochat.ai/papers/10.1210/jc.2012-3074
- The paper
- Slominski, A., Janjetovic, Z., Tuckey, R. C., Nguyen, M. N., Bhattacharya, K. G., Wang, J., Li, W., Jiao, Y., Gu, W., Brown, M., & Postlethwaite, A. E. (2013). 20 S-Hydroxyvitamin D3, Noncalcemic Product of CYP11A1 Action on Vitamin D3, Exhibits Potent Antifibrogenic Activity in Vivo. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2012-3074
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.